Background: The first-in-class recombinant fusion protein IPA blocks WNT signaling by binding WNT ligands. IPA, with Nab-P and G, caused tumor regression in pt-derived PC xenografts. In Phase (P) 1a, IPA was tolerated well with dysgeusia, fatigue, muscle spasms and anorexia as most common adverse events (AEs). Based on vantictumab (VAN, 2nd Wnt inhibitor) data, serum bone turnover markers and/or loss of bone density were used to trigger zoledronic acid (ZA).
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by J. Berlin
A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer
|
By B. H. O'Neil, A. J. Scott, W. W. Ma, S. cohen, D. L. Aisner, A. R. Menter, M. A. Tejani, J. K. Cho, J. Granfortuna, A. L. Coveler, O. O. Olowokure, J. C. Baranda, M. Cusnir, P. Phillip, J. Boles, R. Nazemzadeh, M. Rarick, D. J. Cohen, J. Radford, L. Fehrenbacher, R. Bajaj, V. Bathini, P. Fanta, J. Berlin, A. J. McRee, R. Maguire, F. Wilhelm, M. Maniar, A. Jimeno, C. L. Gomes
|
Annals of Oncology
Verified
We use cookies to enhance your experience on our website. By continuing to use our website, you are agreeing to our use of cookies. You can change your cookie settings at any time. Find out more Skip Navigation A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer B. H. O'Neil, A. J. Scott, W. W. Ma, S. J. Cohen, D. L. Aisner, A. R. Menter, M. A. Tejani, J. K. Cho, J.
A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer
|
By S. cohen, B. H. O'Neil, A. J. Scott, W. W. Ma, D. L. Aisner, A. R. Menter, M. A. Tejani, J. K. Cho, J. Granfortuna, A. L. Coveler, O. O. Olowokure, J. C. Baranda, M. Cusnir, P. Phillip, J. Boles, R. Nazemzadeh, M. Rarick, D. J. Cohen, J. Radford, L. Fehrenbacher, R. Bajaj, V. Bathini, P. Fanta, J. Berlin, A. J. McRee, R. Maguire, F. Wilhelm, M. Maniar, A. Jimeno, C. L. Gomes
|
Annals of Oncology
Verified
We use cookies to enhance your experience on our website. By continuing to use our website, you are agreeing to our use of cookies. You can change your cookie settings at any time. Find out more Skip Navigation A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer B. H. O'Neil, A. J. Scott, W. W. Ma, S. J. Cohen, D. L. Aisner, A. R. Menter, M. A. Tejani, J. K. Cho, J.
Narcissism and celebrity
5. Discussion This is the first study of which we are aware that has obtained data from a reasonably large sample of well-known celebrities regarding their personality characteristics. The results show that celebrities are a highly narcissistic group, with NPI scores significantly higher than that of MBA students. Further, based on Foster et al.’s study of the general population, the celebrity group’s narcissism score was significantly higher than the average U.S. respondent.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with J.
Contact J., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack